10 Years of Successful Partnership between EvidentIQ Germany and Cardialysis in the Field of Clinical Studies

EvidentIQ Germany, formerly known as XClinical, a top provider of EDC software, is proud to mark a decade of fruitful collaboration with Cardialysis, a renowned CRO & Core Laboratory based in the Netherlands.

For the past ten years, EvidentIQ Germany and Cardialysis have joined forces to achieve impressive accomplishments in clinical research. Together, they have enrolled over 46,000 participants in 56 studies spanning various therapeutic areas and study phases, with a primary focus on cardiology.

This decade has seen significant milestones. EvidentIQ introduced Marvin 3.0, featuring a cutting-edge user interface that enhances the efficiency of data capture and management. Additionally, a noteworthy development for Cardialysis was EvidentIQ’s expansion through the merger of several companies into the EvidentIQ Group GmbH. This strategic expansion solidified EvidentIQ‘s position as a leading global provider of EDC software, emphasizing the commitment to continuous innovation.

"The past 10 years have not only been a time of intense collaboration but also an era of innovation and growth for us and Cardialysis," says David Renzelmann, Executive Director Business Development, from EvidentIQ Germany (formerly XClinical).

"Enrolling over 46,000 patients in various studies highlights the importance of our research and its positive impact in the field of cardiology. Relying on robust and secure partners for data collection is crucial for our compliance and quality" adds Dr. Ernest Spitzer, CEO from Cardialysis.

The partnership between EvidentIQ Germany and Cardialysis remains focused on excellence and groundbreaking innovations in clinical research. Both companies look forward to continuing to achieve milestones together, driving innovation in clinical trials and making strides in the field of cardiology.

About Cardialysis: Cardialysis is a Dutch-based, quality-oriented, independent Imaging Core Laboratory and a cardiology-focused, full-service Contract Research Organization (CRO) leveraging from 40 years in the field. It specializes in full-service, multi-national Device(+Pharma) randomized clinical trials. Its services include expert committees’ coordination, including clinical events Committees & data and safety monitoring boards in collaboration with top European and global experts. Cardialysis has a global reach with compliance according to the European, US FDA, PMDA, and CFDA regulations. Cardialysis Core Laboratories specialize in Echocardiography, Cardiac MRI, Computed Tomography, ECG, as well as coronary techniques, including angio-based physiology, angiographic analysis, intravascular ultrasound, and optical coherence tomography. Contact Cardialysis via info@cardialysis.nl.

 

Über die EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.

Firmenkontakt und Herausgeber der Meldung:

EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com

Ansprechpartner:
Sabine Birkner
Marketing Manager
Telefon: +49 89 4522775-250
E-Mail: sabine.birkner@evidentiq.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel